FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS

The Food and Drug Administration approved Tofersen, an investigational drug developed by Biogen and Ionis Pharmaceuticals, to treat a rare genetic form of amyotrophic lateral sclerosis (ALS) Tuesday afternoon.